​美迪西作为领诺医药的合作伙伴，为SLN12140提供了体外药效、药代、安评等一站式临床前研发服务，为该药物尽早进入临床阶段奠定了坚实基础。

上海美迪西生物医药股份有限公司作为清普生物合作伙伴，为美洛昔康注射液（Ⅱ）提供了部分关键临床前研发服务，为其快速获批上市奠定基础。

美迪西作为菌济健康合作伙伴，为LBP-ShC4提供了体内药效、药代、安评等临床前研发服务，助力该项目突破传统研发瓶颈，降低研发成本，加速临床转化进程。

上海美迪西生物医药股份有限公司作为祐森健恒的合作伙伴，为UA026的临床前研发提供了药代动力学、安全性评价服务，以专业高效的技术，为该药快速获批临床奠定了坚实基础。

Dual-targeting chromatin regulation and DNA damage repair signaling presents a promising avenue for cancer therapy. SP-1-303 acts as a class I isoform selective histone deacetylase (HDAC) inhibitor and an activator of the ataxia-telangiectasia mutated protein (ATM). SP-1-303 emerges as a novel second generation class I (HDAC1 and HDAC3) selective HDAC inhibitor, and ATM activator, capable of modulating estrogen receptor (ER) expression, and inhibiting growth of ER+ BC cells. Combined targeting of class I HDACs and ATM by SP-1-303 offers a promising therapeutic approach for treating ER+ breast cancers and supports further preclinical evaluation.

Vertical transmission accounts for most human immunodeficiency virus (HIV) infection in children, and treatments for newborns are needed to abrogate infection or limit disease progression. A hallmark of human immunodeficiency virus type 1 (HIV-1) infection is the early establishment of a persistent viral reservoir1. Daily antiretroviral therapy (ART), the current standard of care, can reduce plasma viral load (PVL) to undetectable levels, but treatment interruption results in viral rebound. Being small molecules, ART drugs rapidly diffuse to distal sites; for instance, DTG was detectable at therapeutically relevant concentrations in colorectal tissue within 1 h of a single oral dose in a Phase I trial.

Clear cell renal cell carcinoma (ccRCC) is the most prevalent histological subtype of kidney cancer and is believed to mainly originate from proximal tubular epithelial cells of the nephron. MTUS1 was significantly downregulated in ccRCC tissues, especially in metastatic tissues. Knockdown of MTUS1 decreased microtubule stability, whereas increased microtubule dynamics by promoting the ratio of unphosphorylated KIF2CS192 adapting to high motility of metastatic cancer cells. MTUS1 is a potent microtubule-stabilizing protein19, so we assessed the impact of MTUS1 knockdown on microtubule dynamics. MTUS1 regulates microtubule dynamics via promoting KIF2CS192 phosphorylation by Aurora B. Western blot and immunohistochemistry further confirmed significantly lower expression of SORBS2 protein in metastatic tissues than that in primary tissues and normal tissues.

Droxytryptamine (5-HT; serotonin) 5-HT3 receptor is an excitatory ligandgated ion channel expressed in for example the brain and the gastrointestinal tract. CSTI-300 as a selective, high affinity 5-HT3 receptor partial agonist. CSTI-300 was examined alongside the selective 5-HT3 receptor antagonist alosetron (which is also currently marketed as a therapeutic for IBS-d). Sub-cutaneous application of 5-hydroxytryptophan (5-HTP; 10 mg/kg) markedly increased the rat’s sensitivity to abdominal contractions. CSTI-300 and Alosetron displayed similar efficacy in a rodent in vivo model of IBS-d, measured by a reduction in colonic sensitivity. The experiments (Rat colon distension model of IBS-d) were carried out by Medicilon. The protocol complied with and was approved by the Institutional Animal Care and Use Committee and Medicilon is accredited by the NIH Office of laboratory Animal Welfare (OLAW) and AAALAC. Experiments (dog behavioural and emesis model) were performed by Medicilon. The protocol for the dog behavioural and emesis model complied with and was approved by the Institutional Animal Care and Use Committee.

Butenolide is a promising antifouling natural product. Rosin-based antifouling paint with the incorporation of butenolide, a promising antifoulant, possesses the potential to deter the settlement of marine organisms on submerged surfaces. Butenolide with a purity >99% was synthesized by Medicilon, Inc. (Shanghai, China).

​Prostanoids are established mediators of inflammation, and the therapeutic efficacy of drugs that block their global biosynthesis in conditions such as rheumatoid arthritis is well-known. AGN 225660 blocks pro-inflammatory prostanoid receptors (DP1, EP1, EP4, FP, TP). AGN 225660 represents a second-generation compound with an “druggable” core structure. AGN 225660 exhibited good ocular bioavailability and was active in reducing ocular inflammation associated with phacoemulsification surgery, lipopolysaccharide (LPS), and arachidonic acid induced uveitis. Ocular Pharmacokinetic studies were performed at Medicilon.